HIV-1各亚型对整合酶抑制剂耐药性的差异。
Differences among HIV-1 subtypes in drug resistance against integrase inhibitors.
作者信息
Han Ying-Shan, Mesplède Thibault, Wainberg Mark A
机构信息
McGill University AIDS Centre, Lady Davis for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada.
McGill University AIDS Centre, Lady Davis for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada; Division of Experimental Medicine, Faculty of Medicine, McGill University, Montreal, Quebec, Canada; Department of Microbiology and Immunology, Faculty of Medicine, McGill University, Montreal, Quebec, Canada.
出版信息
Infect Genet Evol. 2016 Dec;46:286-291. doi: 10.1016/j.meegid.2016.06.047. Epub 2016 Jun 25.
Three integrase strand transfer inhibitors (INSTIs), raltegravir (RAL), elvitegravir (EVG) and dolutegravir (DTG), have been approved by the FDA. Resistance against these three INSTIs have been reported and cross-resistance among them has been documented. Due to extensive and dynamic genetic diversity in different HIV-1 variants, significant differences in susceptibility to the INSTIs have been observed among HIV subtypes. This review summarizes what is known about this topic and discusses possible clinical implications.
三种整合酶链转移抑制剂（INSTIs），即拉替拉韦（RAL）、埃替拉韦（EVG）和多替拉韦（DTG），已获美国食品药品监督管理局（FDA）批准。针对这三种INSTIs的耐药情况已有报道，且它们之间的交叉耐药也有记录。由于不同HIV-1变体存在广泛且动态的基因多样性，在HIV各亚型中观察到对INSTIs的易感性存在显著差异。本综述总结了关于该主题的已知信息，并讨论了可能的临床意义。
Zotero 插件